Kymera Therapeutics (NASDAQ:KYMR) Sets New 12-Month High - Time to Buy?

Key Points

• Kymera Therapeutics reached a new 52-week high, trading near $140 after closing previously at $131.73.
• Analysts have a consensus “Moderate Buy” rating and $139.16 price target, with individual targets ranging from $120 to $180.
• The company missed quarterly estimates, reporting a loss of $1.32 per share versus expectations of $1.26 and revenue of $1.35 million versus $3.28 million expected. Its CEO and another insider also recently sold shares.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) hit a new 52-week high on Monday. The stock traded as high as $138.62 and last traded at $139.9860, with a volume of 685,730 shares traded. The stock had previously closed at $131.73.

Analyst Ratings Changes

A number of research firms have recently issued reports on KYMR. Loop Capital set a $132.00 target price on Kymera Therapeutics in a research note on Thursday, October 29th. Mizuho boosted their price target on Kymera Therapeutics from $120.00 to $140.00 and gave the stock an "outperform" rating in a research report on Thursday, July 16th. Raymond James Financial restated an "outperform" rating on shares of Kymera Therapeutics in a research note on Thursday, October 29th. Deutsche Bank Aktiengesellschaft initiated coverage on Kymera Therapeutics in a research report on Thursday, July 30th. They set a "hold" rating and a $120.00 target price on the stock. Finally, Wolfe Research upgraded Kymera Therapeutics from a "peer perform" rating to an "outperform" rating and set a $180.00 price target on the stock in a research note on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $139.16.

Kymera Therapeutics Stock Up 6.2%

The firm has a market cap of $11.95 billion, a P/E ratio of -38.55 and a beta of 2.04. The business's 50 day moving average is $115.68 and its 200-day moving average is $97.81.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The company reported ($1.32) EPS for the quarter, missing analysts' consensus estimates of ($1.26) by ($0.06). The company had revenue of $1.35 million for the quarter, compared to the consensus estimate of $3.28 million. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 22.39%. The company's revenue was up .0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.94) earnings per share. As a group, equities analysts predict that Kymera Therapeutics, Inc. will post -3.88 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Nello Mainolfi sold 30,000 shares of the business's stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $113.80, for a total value of $3,414,000.00. Following the completion of the sale, the chief executive officer directly owned 666,568 shares in the company, valued at approximately $75,855,438.40. The trade was a 4.31% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Brian Adams sold 6,371 shares of the company's stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $116.83, for a total value of $744,323.93. Following the sale, the insider directly owned 50,254 shares in the company, valued at approximately $5,871,174.82. This represents a 11.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 15.98% of the company's stock.

Institutional Trading of Kymera Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Eurizon Capital SGR S.p.A. acquired a new stake in Kymera Therapeutics in the 3rd quarter valued at approximately $37,000. GAMMA Investing LLC increased its holdings in shares of Kymera Therapeutics by 27.5% during the second quarter. GAMMA Investing LLC now owns 454 shares of the company's stock valued at $52,000 after purchasing an additional 98 shares during the period. Fulcrum Asset Management LLP bought a new stake in shares of Kymera Therapeutics during the third quarter valued at about $65,000. IFP Advisors Inc raised its stake in shares of Kymera Therapeutics by 236.5% during the third quarter. IFP Advisors Inc now owns 737 shares of the company's stock valued at $82,000 after purchasing an additional 518 shares in the last quarter. Finally, PNC Financial Services Group Inc. lifted its holdings in Kymera Therapeutics by 56.3% in the first quarter. PNC Financial Services Group Inc. now owns 1,285 shares of the company's stock worth $107,000 after purchasing an additional 463 shares during the period.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical-stage biotechnology company developing medicines that selectively remove disease-causing proteins from cells. Its approach, known as targeted protein degradation, uses the body's natural protein-disposal system and is designed to address targets that may be difficult to reach with conventional drugs.

The company's research and development programs include small-molecule protein degraders for conditions involving immune and inflammatory pathways, as well as cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.